Resolutions adopted at the annual general meeting of Hansa Medical AB (publ)
N.B. the English version below is an office translation. In case of any discrepancy between the Swedish and the English version, the Swedish version shall prevail.
The following resolutions, among others, were adopted by the annual general meeting of Hansa Medical AB (publ) held on 23 May 2017.
Dividend
The annual general meeting resolved that no dividend will be paid for the financial year 2016.
Discharge from liability
The annual general meeting granted the directors and CEO discharge from liability in respect of the 2016 financial year.
Board of directors and auditor
The annual general meeting resolved to re-elect Stina Gestrelius, Angelica Loskog, Hans Schikan, Birgit Stattin Norinder, Per Olof Wallström and Ulf Wiinberg as Board members. Ulf Wiinberg was re-elected chairman of the Board. The annual general meeting resolved to re-elect KPMG AB in Malmö as the company’s auditor.
The annual general meeting resolved on remuneration to the Board as follows. Remuneration to the Board members: SEK 600,000 to the Chairman of the Board and SEK 150,000 each to the other Board Members, except for Angelica Loskog. Remuneration to the Board committees: SEK 40,000 to the chairman and SEK 30,000 each to the other Board Members in the audit committee, SEK 40,000 to the chairman and SEK 25,000 each to the other Board Members in the Remuneration Committee and SEK 25,000 each to the Board Members in the Scientific Committee. A Board Member may, if it is in accordance with current tax legislation and provided it is cost neutral for the company, be given the possibility to invoice the remuneration from his own company, provided the company is registered for corporate tax (sw. F-skatt). Social contributions fees and VAT will be added to such remuneration invoiced by Board Member within a business operation. The annual general meeting furthermore resolved on remuneration to the auditor according to an authorized account.
In addition, the annual general meeting also adopted resolutions regarding instructions for the nomination committee as well as guidelines regarding compensation to senior executives.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: +46 70-633 30 42
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project IdeS is a proprietary antibodydegrading enzyme currently in late- stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and a wide range of acute autoimmune indications. The company also has a strong pipeline of preclinical assets that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing translating the Hansa Medical technology into relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.
Tags: